Abstract
Administration of Prophylactic vaccines still is the cutting-edge of prevention, control and elimination of infections. Among the common causes of sexually transmitted diseases, chlamydia trachomatis is an important socioeconomic burden worldwide which impairs human genital tract function, resulting in severe complications like urethritis, pelvic inflammatory disease (PID), getting ease of HIV transmission, playing cofactor role in human papilloma virus (HPV)- induced cervical neoplasia, and unfortunately infertility. Because of all difficulties, vaccination is considered to be the most economical and reliable way to escape from unrestrained exacerbation states of infection than any other prevalence program. But despite much advancement in the field of veterinary, the dream has yet to be realized. Among a number of potential candidates, the major outer membrane protein (MOMP) is a vanguard of subunit vaccines. In this attempt, MOMP216 gene fragment cloned in PET28b+ and expressed in E.coli. The protein expression confirmed by SDS-PAGE. These findings demonstrate that, considering the antigenicity prediction and due to the existence of potential epitopic region, rMOMP216 could be a potential capable peptide which can represent as an alternative to whole MOMP.
Highlights
Worldwide hurricane of 92 million cases of chlamydia trachomatis infection was estimated by WHO in 2001 [1]
The perfect protection model is focused on subunit vaccine using major outer membrane protein (MOMP) [9]
SDS-PAGE were shown to have one band corresponded to recombinant protein which were termed as rMOMP217 (Table 1)
Summary
Worldwide hurricane of 92 million cases of chlamydia trachomatis infection was estimated by WHO in 2001 [1]. High prevalence of sexually transmitted infections in Europe [2] and in the United States [3] would recommend it as a leading cause of cervicitis, pelvic inflammatory disease (PID), Salpingitis, ectopic pregnancy and infertility [4]. It is too prevalent in developing countries [5]. Our suggestion is that MOMP160-376 which named rMOMP217 during this paper would be a new member of potentially vaccine candidate among collection investigated during so many years. Undoubtedly this present study needs further experimental works to develop an effective vaccine instead of both therapeutic and prophylactic proceedings
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
